TCMP
GILD icon

Thrive Capital Management (Pennsylvania)’s Gilead Sciences GILD Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.24M Sell
30,427
-3,550
-10% -$497K 0.93% 39
2025
Q4 		$4.17M Sell
33,977
-3,100
-8% -$377K 0.93% 36
2025
Q3 		$4.12M Buy
37,077
+6,314
+21% +$718K 1.06% 33
2025
Q2 		$3.41M Buy
30,763
+14,029
+84% +$1.49M 1.07% 27
2025
Q1 		$1.87M Sell
16,734
-11,451
-41% -$1.18M 1.12% 17
2024
Q4 		$2.6M Buy
28,185
+2,853
+11% +$257K 1.19% 27
2024
Q3 		$2.12M Sell
25,332
-4,371
-15% -$334K 1% 22
2024
Q2 		$2.04M Buy
29,703
+12,186
+70% +$813K 0.93% 27
2024
Q1 		$1.28M Buy
17,517
+14,731
+529% +$1.13M 0.68% 25
2023
Q4 		$226K Sell
2,786
-219
-7% -$17K 0.12% 134
2023
Q3 		$225K Buy
3,005
+87
+3% +$6.69K 0.12% 123
2023
Q2 		$225K Sell
2,918
-1,900
-39% -$152K 0.13% 125
2023
Q1 		$392K Sell
4,818
-3,987
-45% -$330K 0.25% 75
2022
Q4 		$756K Sell
8,805
-1,461
-14% -$116K 0.49% 44
2022
Q3 		$633K Buy
10,266
+4,425
+76% +$279K 0.43% 48
2022
Q2 		$361K Buy
+5,841
New +$362K 0.25% 66

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Thrive Capital Management (Pennsylvania)'s GILD Position: Q1 2026 in Review

Thrive Capital Management (Pennsylvania) reduced its Gilead Sciences (GILD) stake by 10% in Q1 2026, selling an estimated $497K and leaving 30,427 shares worth $4.24M. The position accounts for 0.93% of the portfolio, ranked #39.

Thrive Capital Management (Pennsylvania) first reported a position in GILD in Q2 2022 and has held it in 16 quarters since. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Thrive Capital Management (Pennsylvania) held 30,427 shares of Gilead Sciences worth $4.24M as of Q1 2026.
  • Thrive Capital Management (Pennsylvania) sold 3,550 Gilead Sciences shares in Q1 2026, an estimated $497K.
  • Gilead Sciences made up 0.93% of Thrive Capital Management (Pennsylvania)'s portfolio in Q1 2026, its #39 holding.
  • Thrive Capital Management (Pennsylvania) first reported a position in Gilead Sciences in Q2 2022 and has held it in 16 quarters since.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q1 2026, filed 27 Apr 2026.